Navigation Links
The Galien Foundation Announces 2013 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology"

NEW YORK, July 25, 2013 /PRNewswire/ -- The Galien Foundation today announced the 2013 nominees for the seventh annual Prix Galien Awards. The Prix Galien Award is considered the biomedical industry's highest accolade and recognizes the technical, scientific and clinical research skills necessary to develop innovative medicines and devices.

(Logo: )

This year brings the highest number of nominees since the inception of the Prix Galien USA – a reflection of the United States continuing to lead the world in first approval of new medicines.  Ranging from a tablet drug for the treatment of metastatic colorectal cancer, to a ground-breaking treatment for cystic fibrosis, and the first and only drug available to reduce toxic plasma methotrexate levels, nominees include biomedical products that advance the human condition and which were approved by the U.S. Food and Drug Administration (FDA) during the past five years.

Nominees for the Prix Galien USA 2013 Awards are: Best Biotechnology Product (Nominees)BOTOX® (onabotulinumtoxinA) for Chronic MigraineAllergan, Inc.Voraxaze® (glucarpidase)BTG International Inc.MenHibrix® [Meningococcal Groups C and Y and
Haemophilus b Tetanus Toxoid Conjugate Vaccine]

GlaxoSmithKline VaccinesErwinaze® (asparaginase Erwinia chrysanthemi)

Jazz PharmaceuticalsFluMist® Quadrivalent

(Influenza Vaccine Live, Intranasal)MedImmune/AstraZenecaZostavax® (Zoster Vaccine Live)Merck 

HEMACORD™ (HPC, Cord Blood)New York Blood Center's
Howard P. Milstein Cord Blood CenterGattex® (teduglutide)NPS PharmaceuticalsKyprolis® (carfilzomib) for Injection

Onyx Pharmaceuticals, Inc.Gintuit™ (Allogeneic Cultured Keratinocytes and
Fibroblasts in Bovine Collagen)

OrganogenesisKineret® (anakinra)

SobiTbo-filgrastim (XM02)

Teva PharmaceuticalsJETREA® (ocriplasmin)

ThromboGenicsBest Pharmaceutical Agent (Nominees)AMPYRA® (dalfampridine)
Extended Release Tablets, 10 mg

Acorda TherapeuticsBELVIQ® (lorcaserin HCl)

Arena PharmaceuticalsCAPRELSA® (vandetanib)

AstraZenecaStivarga® (regorafenib)

Bayer HealthCareEliquis® (apixaban)Bristol-Myers Squibb & PfizerBanzel® (rufinamide)EisaiZelboraf® (vemurafenib)GenentechSirturo® (bedaquiline)JanssenXarelto® (rivaroxaban)JanssenZytiga® (abiraterone acetate)JanssenXtandi® (enzalutamide)

MedivationXALKORI® (crizotinib)

PfizerXeljanz® (tofacitinib)

(reformulated oxycodone HCl controlled release)

Purdue PharmaNeupro® (Rotigotine Transdermal System)

UCBVimpat® (lacosamide) CV

UCBKALYDECO™ (ivacaftor)

Vertex PharmaceuticalsBest Medical Technology (Nominees)COMBIVENT® RESPIMAT®
(ipratropium bromide and albuterol) Inhalation SprayBoehringer IngelheimAlair® Bronchial Thermoplasty SystemBoston ScientificS-ICD® System
(subcutaneous implantable defibrillator)Boston ScientificNovoTTF™ Therapy

Novocurecoflex® Interlaminar Stabilization™ deviceParadigm Spine, LLCElecsys® Testosterone IIRoche Auvi-Q™ (epinephrine injection, USP)Sanofi  Trevo® ProVue™ RetrieverStrykerCentraSight®VisionCare 

The Prix Galien USA Committee, comprised of nine renowned leaders in biomedical industry and academia, including five Nobel Laureates, is responsible for evaluating nominees. Winners will be honored at the Prix Galien Award Ceremony on October 22, 2013 at 6:00 p.m., at the American Museum of Natural History in New York City.  Registration is open to the Prix Galien USA Award Ceremony and can be accessed here.

"Biomedical research cannot exist without those who are willing to push innovation and extract understanding and attention in the details," remarked Bruno Cohen, Chairman of the Galien Foundation.  "This year's nominees are catalysts for the development of disease-altering advances through biopharmaceutical and medical innovation.  We are proud to honor those in the field who exemplify these values; the same values that the Galien Foundation continually upholds, distinguishing these awards as the best in the world."

About the Galien Foundation
The Galien Foundation fosters, recognizes and rewards excellence in scientific innovation to improve the state of human health. Our vision is to be the catalyst for the development of the next generation of innovative treatment and technologies that will impact human health and save lives.

The Foundation oversees and directs activities in the USA for the Prix Galien, an international award that recognizes outstanding achievements in improving the human condition through the development of innovative therapies. The Prix Galien was created in 1970 in honor of Galen, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research.

For more information visit

Galien Foundation Media Contact:
Jon Florio

SOURCE Galien Foundation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. NIH Director Francis S. Collins, M.D., Ph.D. Selected as 2012 Pro Bono Humanum Honoree by Prix Galien USA
2. The Galien Foundation Announces Roster of Luminary Presenters for Third Galien Forum; Program Highlights Include CEO Panel, Panel on Alzheimers Disease Innovation, Nobel Laureate Elie Wiesel
3. The Galien Foundation Announces New "Best Medical Technology" Award Category for 2012 Prix Galien USA Awards Program
4. Organovo and Methuselah Foundation Announce Funding of Bioprinting Research at Research Institutions
5. National Association of Specialty Pharmacy (NASP) Partners with the Patient Access Network (PAN) Foundation to Host Charity Golf Outing at Upcoming Meeting
6. WED/RLS Foundation Sheds Light On TranquilMeds Drug-free Solution
7. Austen BioInnovation Institute Gains Funding from The Burton D. Morgan Foundation to Accelerate Biomedical Innovation, Train Young Professionals
8. Promising Parkinsons Disease Research Highlighted by The Michael J. Fox Foundation to Accelerate Drug Development
9. Epilepsy Foundation Launches The "Epilepsy Innovation Seal Of Excellence" Recognizing Groundbreaking Product Candidates For People With Epilepsy
10. Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
11. Ellen MacArthur Foundation presenterar Philips som global partner vid det konstituerande internationella toppmötet om cirkulär ekonomi
Post Your Comments:
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/24/2016)... Calif. , June 24, 2016  Global ... a biopharmaceutical company developing novel therapeutics for the ... needs, today announced the closing of its previously ... common stock, at the public offering price of ... the offering were offered by GBT. GBT estimates ...
(Date:6/24/2016)... 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... markets and sells medical devices and wearable sleep respiratory ... strategic cooperation agreement with Hongyuan Supply Chain Management Co., ... June 20, 2016, to develop Dehaier,s new Internet medical ... Dehaier will leverage Hongyuan Supply Chain,s sales platform to ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, ... Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility ... home to some of the world’s leading providers of cereal and other breakfast foods. ...
(Date:6/26/2016)... Charlotte, NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind ... able to be personalized through a fitness app. The fitness app plans to fix the ... solutions currently only offer a one size fits all type program , They ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
Breaking Medicine News(10 mins):